The Lancet Haematology

Correction to Lancet Haematol 2025; 12: e562-63.

Pub Date : 2025-08-13 DOI: 10.1016/s2352-3026(25)00234-0

Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, single-arm, phase 2 trial.

Pub Date : 2025-08-07 DOI: 10.1016/s2352-3026(25)00172-3 Marie Robin,Maud D'Aveni,Aspasia Stamatoullas,Emmanuel Raffoux,Patrice Chevallier,Alice Garnier,Clémence Mediavilla,Martin Carre,Chantal Himberlin,Marie Sébert,Aurélie Ravinet,Kristell Desseaux,Hélène Labussière,Mustafa Alani,Marie-Thérèse Rubio,Anne Huynh,Lionel Adès,Régis Peffault de Latour,Franciane Paul,Fatiha Chermat,Raphael Petit,Chama Mokeddem,Amandine Charbonnier,Sylvain Thépot,Sylvie Chevret,Pierre Fenaux,

Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.

Pub Date : 2025-08-01 DOI: 10.1016/s2352-3026(25)00162-0 Sara Bringhen,Lorenzo Cani,Elisabetta Antonioli,Daniele Derudas,Francesca Fazio,Alessandra Larocca,Sonia Ronconi,Claudia Cellini,Antonietta Pia Falcone,Fabrizio Accardi,Anna Marina Liberati,Piero Galieni,Angelo Belotti,Anna Maria Cafro,Roberto Ria,Giulia Benevolo,Iolanda Donatella Vincelli,Donato Mannina,Flavia Lotti,Benedetto Bruno,Vincenzo Marasco,Rita Mazza,Patrizia Tosi,Elena Rivolti,Mario Boccadoro,Mattia D'Agostino